“…MiR-138 has been reported to play a suppressive role in certain common types of human cancer, including brain cancer, osteosarcoma, cervical cancer, larynx carcinoma, and lung cancer, and so on ( Sha et al, 2017 ; Yeh et al, 2019 ), and is considered to be a promising therapeutic target for cancer. The suppressive function of miR-138 was found to target enhancer of zeste homolog 2 (EZH2) ( Zhang et al, 2013 ; Si et al, 2017 ), pyruvate dehydrogenase kinase 1 and G protein-coupled receptor 124 (GPR124) ( Gao et al, 2014 ; Ye et al, 2015 ), SP1 ( Liu et al, 2018 ), SOX9 ( Hu et al, 2017 ), and cyclin D3 ( Huang et al, 2015 ) to inhibit tumor cell growth and migration. Although some studies showed that over-expression of miR-138 in CD4 + T cells from psoriasis patients decreased the amounts of Th1/Th2 cells ( Fu et al, 2015 ), and miR-138 in T cells also targeted PD-1 and CTLA-4 to regulate T cell tolerance ( Wei et al, 2016 ).…”